Articles | Volume 3, issue 1
Primate Biol., 3, 9–22, 2016
https://doi.org/10.5194/pb-3-9-2016
Primate Biol., 3, 9–22, 2016
https://doi.org/10.5194/pb-3-9-2016

Review article 12 Feb 2016

Review article | 12 Feb 2016

The common marmoset (Callithrix jacchus): a relevant preclinical model of human (auto)immune-mediated inflammatory disease of the brain

Bert A. 't Hart et al.

Related subject area

Immunology
Experimental autoimmune encephalomyelitis in the common marmoset: a translationally relevant model for the cause and course of multiple sclerosis
Bert A. 't Hart
Primate Biol., 6, 17–58, https://doi.org/10.5194/pb-6-17-2019,https://doi.org/10.5194/pb-6-17-2019, 2019
Short summary
Use of nonhuman primates in obstructive lung disease research – is it required?
Franziska Dahlmann and Katherina Sewald
Primate Biol., 4, 131–142, https://doi.org/10.5194/pb-4-131-2017,https://doi.org/10.5194/pb-4-131-2017, 2017

Cited articles

Arnon, R., Sela, M., and Teitelbaum, D.: New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis, J. Neurol., 243, 8–13, 1996.
Ascherio, A. and Munger, K. L.: Environmental risk factors for multiple sclerosis. Part I: the role of infection, Ann. Neurol., 61, 288–299, 2007a.
Ascherio, A. and Munger, K. L.: Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors, Ann. Neurol., 61, 504–513, 2007b.
Ascherio, A. and Munger, K. L.: EBV and Autoimmunity, Curr. Top. Microbiol. Immunol., 390, 365–385, 2015.
Ascherio, A., Munger, K. L., and Lunemann, J. D.: The initiation and prevention of multiple sclerosis, Nat. Rev. Neurol., 8, 602–612, 2012.
Download
Short summary
The increasing prevalence of chronic autoimmune inflammatory disorders (AIMIDs) in aging human populations creates a high unmet need for safe and effective medications. However, thus far the translation of pathogenic concepts developed in animal models into effective treatments for the patient has been notoriously difficult. The main reason is that currently used mouse-based animal models for the pipeline selection of promising new treatments were insufficiently predictive for clinical success.